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AbstrACt
Objective To compare the medium-term clinical 
effectiveness of total hip arthroplasty and resurfacing 
arthroplasty.
Design Single centre, two-arm, parallel group, assessor 
blinded, randomised controlled trial with 1:1 treatment 
allocation.
setting A large teaching hospital in England.
Participants 122 patients older than 18 years with 
severe arthritis of the hip joint, suitable for resurfacing 
arthroplasty of the hip. Patients were excluded if they were 
considered to be unable to adhere to trial procedures or 
complete questionnaires.
Interventions Total hip arthroplasty (replacement of 
entire femoral head and neck); hip resurfacing arthroplasty 
(replacement of the articular surface of femoral head only, 
femoral neck remains intact). Both procedures replaced 
the articular surface of the acetabulum.
Outcomes The outcome measures were hip function 
assessed using the Oxford Hip Score (OHS) and health-
related quality of life assessed using the EuroQol (EQ-5D). 
Patients were followed up annually for a minimum of 5 
years. Outcome data were modelled using the generalised 
estimating equation methodology to explore temporal 
variations during follow-up.
results 60 patients were randomly assigned to hip 
resurfacing arthroplasty and 62 to total hip arthroplasty. 
95 (78%) of the 122 original study participants provided 
data at 5 years. There was a small decrease in both hip 
functions and quality of life in both groups of patients 
each year during the 5-year follow-up period. However, 
there was no evidence of a significant difference between 
treatments group in the OHS (P=0.333) or the EQ-5D 
(P=0.501).
Conclusions We previously reported no difference 
in outcome in the first year after surgery. The current 
medium-term results also show no evidence of a 
difference in hip function or health-related quality of life 
in the 5 years following a total hip arthroplasty versus 
resurfacing arthroplasty.
trial registration number ISRCTN33354155. UKCRN 
4093.
IntrODuCtIOn 
For older patients with severe arthritis of 
the hip, several designs of total hip arthro-
plasty (THR) have shown excellent long-term 
results in terms of both function and value for 
money.1 However, in younger and more active 
patients, there is an approximate 50% failure 
rate at 25 years for traditional implants.2 
Modern THR designs may improve on these 
results,3 but the search for new, more durable 
forms of arthroplasty continues. One option 
is resurfacing arthroplasty of the hip (RSA).4 
Resurfacing implants are more expensive 
than traditional (metal and plastic) THR 
designs and there are potential complications 
associated with RSA compared with THR—
most importantly the risk of fracture of the 
neck of the femur.5 However, the first clin-
ical results showed that in selected patients, 
98% of RSA implants were still functioning at 
5 years6; which is as good as any of the existing 
THR designs.1 Furthermore, by preserving 
the patient’s own proximal femoral anatomy, 
it was suggested that RSA may provide more 
physiological hip movement. Early clin-
ical outcomes indicated that RSA provides 
strength and limitations of this study
 ► The main strength of this trial is that it is pragmatic, 
with a large number of surgeons using a variety of 
different hip arthroplasty implants and their own 
preferred surgical technique.
 ► Other strengths include the use of validated patient-
reported outcome tools, a relatively large number of 
participants for this type of trial and the high levels 
of complete follow-up data.
 ► The key limitation of this trial was that the patients 
themselves could not be blind to their type of hip 
arthroplasty.
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improved hip function when compared with THR.7 8 
Other studies7 9 reported that patients having RSA had 
higher activity levels after the procedure and were more 
likely to be involved in activities such as running and 
heavy manual labour. However, these studies were not 
randomised clinical trials.
In 2012, we reported the 1 year results of a randomised 
controlled trial to compare the clinical effectiveness THR 
and RSA in patients with severe arthritis of the hip.10 
There was no evidence of a difference in functional 
outcomes or health-related quality of life at 1 year. Data 
regarding cost-effectiveness were reported separately.11 
In this report, we provide the minimum 5-year follow-up 
data from the same cohort of patients randomised into 
the original trial.
PAtIents AnD methODs
This was a single-centre, two-arm, parallel group, asses-
sor-blind randomised controlled trial with 1:1 treat-
ment allocation conducted in the UK. Full details of the 
protocol have been described previously.12 A summary of 
the methodology follows below.
study population
In this pragmatic trial, participants were eligible if they 
were over 18 years of age, medically fit for an operation 
and suitable for a RSA—patients suitable for RSA are 
also suitable for THR. Patients were only excluded from 
the study if there was evidence that the patient would be 
unable to adhere to trial procedures or complete ques-
tionnaires. To maintain independence between observed 
outcomes, if a recruited patient required a contralateral 
hip arthroplasty during the trial period the second hip 
was not included in the study.
recruitment and randomisation of participants 
The Warwick Arthroplasty Trial (WAT) opened in May 
2007 and 126 patients were recruited between August 
2007 and February 2010 from hip arthroplasty clinics 
in a single UK hip arthroplasty centre. Eligible patients 
gave written informed consent. They were randomised 
on a 1:1 basis to receive either a THR or an RSA. Treat-
ment allocation was determined using a computer-gener-
ated, randomised number sequence and stratified by the 
supervising orthopaedic surgeon to balance any potential 
surgeon effects. After patients consented to participate in 
the trial, an independently administered, secure rando-
misation service was alerted by telephone of a new enrol-
ment. The randomisation officer provided the surgeon’s 
secretary with the patient’s treatment allocation, thereby 
keeping the research associates, who consented patients 
and collected outcome data, blinded to the allocated 
treatment.
Interventions 
Each patient had the allocated surgery according to 
the preferred technique and implants of the operating 
surgeon. Other perioperative interventions, such as 
prophylactic antibiotics and thromboprophylaxis, were 
the same for all patients. After the operation, all patients 
underwent the same standardised rehabilitation plan, 
including range-of-movement exercises followed by 
muscle strengthening exercises. Unless the operating 
surgeon specifically advised otherwise, all patients were 
fully weight bearing immediately.
In a THR, the femoral head was removed along with 
most of the femoral neck. The femoral shaft was exposed 
to open up the femoral canal. The femoral component was 
then inserted into the canal and the articulating femoral 
head was placed onto the neck of the femoral compo-
nent. The choice of components and bearing surfaces 
was left to the discretion of the operating surgeon, as per 
their usual clinical practice.
In a resurfacing arthroplasty, the articular surfaces of 
the femoral head was removed but the neck was left in 
situ. The femoral component (cap) was then impacted 
onto the patient’s own femoral neck. All resurfacing 
arthroplasties of the hip used metal-on-metal bearing 
surfaces, but the choice of surgical approach, implant size 
and positioning was left to the discretion of the operating 
surgeon.
In both forms of arthroplasty, the acetabulum is 
prepared and the acetabular component inserted into 
the socket.
Outcome measurements 
The primary outcome measure for this medium-term 
follow-up study was hip function, assessed using the 
OHS,13 and the secondary outcome was the EuroQol 
5D (EQ-5D) health-related quality of life utility score 
(HRQoL).14 Each outcome was collected annually by 
self-reported postal questionnaire. All complications 
related to the hip arthroplasty were recorded during the 
course of the trial.
On completion of the main phase of the trial, the trial 
steering group recommended to remove the additional 
outcomes collected during main phase (Harris Hip 
Score, Disability Rating Index, physical activity level and 
resource use) to reduce the burden on the participants 
and to optimise retention rates.
statistical analysis 
Longitudinal data (ie, the time course of measurements 
at yearly intervals) were modelled using generalised 
estimating equations (GEEs) to explore the popula-
tion-averaged effects of time and operative treatment 
on function and HRQoL.15 A first-order autoregressive 
working correlation model was adopted to account for 
within-subject temporal correlations of untransformed 
OHS and EQ-5D outcomes, which were assumed to be 
approximately normally distributed and related to the 
linear predictor using the identity link function. Statis-
tical significance was assessed at the 5% level and CIs 
of estimated temporal trends in OHS and EQ-5D were 
constructed by non-parametric bootstrapping. Models 
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with smaller a quasilikelihood information criteria (QIC) 
were considered to be better descriptors of the data.15 
Differences in complication rates between groups were 
assessed using Fisher’s exact test. All analyses were under-
taken in R V.3.2.2.16
results
The WAT study recruited 126 participants, 95% of whom 
had a primary diagnosis with osteoarthritis. Of the 126 
participants recruited into the WAT study, 4 never had 
an operation, leaving 122 in total available for follow-up 
during the original trial and in the extended (medi-
um-term) follow-up study that we report here. The base-
line characteristics of these 122 participants are shown in 
table 1.
The following medium-term follow-up results are based 
on the treatment received (per-protocol analysis), in 
contrast to the previously reported study results which 
were based on the allocated intervention (ie, intention-to-
treat analysis). The amount of missing data at each time-
point is shown in table 2. A small number of patients died 
during follow-up, did not respond to attempts to contact 
them or actively asked to be withdrawn from the study. 
In total, 95 (78%) of the 122 original study participants 
provided data at 5 years. We have no reason to believe 
that withdrawals or loss was related to the intervention, 
so we will assume for purposes of analysis that data were 
missing completely at random.
Ohs
OHS scores at each year postoperation (from year 1 to 
5) were strongly positively autocorrelated; that is, a high 
OHS at year 1 was predictive of a high OHS in subsequent 
years. The OHS scores decreased over time from year 1 to 
year 5 (GEE z-test of regression coefficients; P=0.003, with 
the regression coefficient −0.70). However, this decline 
was unlikely to be clinically relevant in the medium term, 
occurring at only approximately 0.70 OHS units per year. 
Figure 1 shows the temporal trends in OHS for partici-
pants from operation to year 5.
Adding model terms to account for treatment groups 
(RSA vs THR) did not lead to a reduction in QIC, and 
model parameters showed that there was no evidence 
of a significant difference between treatment groups 
(P=0.333) during follow-up, and the rate of decline of OHS 
Table 1 Baseline characteristics of 122 participants by 
received intervention; data shown are means (SD)10
Treatment RSA (n=60) THR (n=62)
Sex F=24 and M=36 F=27 and M=35
Age (years) 56.5 (6.9) 56.7 (7.0)
BMI (kg/m2) 28.4 (6.2) 28.9 (4.8)
Oxford Hip Score 19.0 (7.7) 19.3 (7.9)
EQ-5D score 0.31 (0.35) 0.36 (0.36)
EQ-5D VAS 56.1 (23.4) 57.6 (24.2)
BMI, body mass index: EQ-5D, EuroQoL Five Dimensions; RSA, 
resurfacing arthroplasty of the hip; THR, total hip arthroplasty; VAS, 
visual analogue scale. 
Table 2 Patient follow-up at yearly intervals postoperation
Patient status
Year of follow-up
1 2 3 4 5
RSA THR RSA THR RSA THR RSA THR RSA THR
Died 0 0 0 0 1 0 1 0 1 0
Missing* 0 0 7 5 6 2 7 5 11 11
Responded† 60 62 53 57 53 59 50 56 45 50
Withdrawn 0 0 0 0 0 1 2 1 3 1
Total 60 62 60 62 60 62 60 62 60 62
*Missing data, lost to follow-up.
†Patient followed-up.
RSA,  resurfacing arthroplasty of the hip; THR,  total hip arthroplasty.
Figure 1 Temporal trends in Oxford Hip Score for 
participants from operation to year 5. RSA,  resurfacing 
arthroplasty of the hip;  THR,  total hip arthroplasty. 
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score did not differ between treatment groups (P=0.317). 
Full results of analyses are shown in online supplemen-
tary appendix A1.
hrQol 
There was also evidence for a significant temporal change 
in EQ-5D (GEE z-test of regression coefficients; P=0.002); 
EQ-5D scores decreased over time from year 1 to year 
5 (regression coefficient −0.027). However, again the 
decline in EQ-5D scores was relatively small at approxi-
mately 0.027 units per year.
EQ-5D scores showed considerable variability during 
follow-up (figure 2). Adding model terms to account for 
treatment groups did not lead to a reduction in QIC, and 
model parameters showed that there was no evidence for 
a statistically significant difference between treatments 
groups (P=0.501). The rate of decline of EQ-5D scores did 
not differ between treatment groups (P=0.236). Full results 
of analyses are shown in  online supplementary appendix 
A2.
Complications 
During the 5-year follow-up, one patient in the RSA group 
had a revision arthroplasty and three in the THR group 
(table 3). Two other patients in the THR group suffered a 
dislocation of the hip but did not require revision surgery. 
One patient in the RSA group had an aspiration of the 
hip joint but did not require revision surgery.
Fisher’s exact test provides no evidence of a statistically 
significant difference in revision rates between treatment 
groups (P=0.619).
DIsCussIOn
Our previously reported randomised clinical trial found 
no evidence of a difference in hip function between 
patients having THR versus RSA for severe arthritis of 
the hip joint during the first year following surgery.10 
This medium-term follow-up study continues to show no 
difference in hip function at 5 years. Similarly, there was 
no difference in HRQoL. The number of further compli-
cations after the first year was low in both groups, but one 
patient in the RSA group and three in the THR group 
required revision arthroplasty surgery.
Only a few randomised trials have been performed 
comparing THR with the resurfacing technique. The 
first studies focused on the technical aspects of the 
procedure, such as the position of the implants or the 
amount of bone removed during the resurfacing proce-
dures.17 18 Three trials investigated clinical outcomes for 
resurfacing arthroplasty compared with a specific type 
of THR, namely metal-on-metal THR.19–21 All of these 
trials showed little difference in functional outcome 
between the groups in the first 1 to 2 years after surgery. 
Each of the trials included plans to perform longer term 
follow-up of the participants. However, subsequent, 
widely reported concerns regarding the adverse effects of 
metal debris from metal-on-metal bearing surfaces have 
made it difficult to interpret any later results from these 
trials22 23; particularly because the functional deficits asso-
ciated with adverse reactions to metal debris seemed to 
be greater in one group (THR) than the other (RSA).24
A further randomised trial25 looked at early muscle 
strength in 43 patients and found greater muscle 
strength deficits in the RSA group. In contrast, a trial 
of 80 patients with dysplastic acetabula found improved 
early range of movement in the RSA group although 
with no difference in functional hip scores.26
The only longer term follow-up study of resurfacing 
versus conventional bearing-surface THR showed no 
difference between groups with regard to OHS or 
quality life.27 More patients in the resurfacing group 
were involved in impact activities. However, this study 
contained only 24 randomised patients.
The main strength of this trial is that it is entirely 
pragmatic, with a relatively large number of surgeons 
using a variety of different hip arthroplasty implants 
and their own preferred surgical technique. Although 
the patients were recruited from only one centre, the 
large number of surgeons involved and the variety 
of implants is likely to reflect practice in the wider 
surgical community. Other strengths include the use of 
Figure 2 Temporal trends in EQ-5D for participants from 
operation to year 5.  EQ-5D, EuroQoL Five Dimensions; RSA, 
resurfacing arthroplasty of the hip; THR, total hip arthroplasty.
Table 3 Revisions at 5 years by treatment group
RSA THR Total
Revised 1 3 4
Unrevised 44 47 91
Total 45 50 95
RSA, resurfacing arthroplasty of the hip; THR, total hip 
arthroplasty. 
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validated patient-reported outcome tools, a relatively 
large number of participants and the high levels of 
complete follow-up data.
The key limitation of this trial was that the patients 
themselves were not blind to their type of hip arthro-
plasty. Patients undergoing RSA in the UK have gener-
ally been given a different preoperative information 
sheet and surgical consent from than those having a 
THR; this reflects the existing evidence regarding the 
different risk/benefit profile of the two procedures.
How do the results of this trial inform the debate 
about resurfacing arthroplasty of the hip? This trial 
failed to show any evidence that resurfacing arthroplasty 
provides improved hip function or greater quality of life 
when compared with THR over 5 years. Given the new 
requirements for surveillance of metal-on-metal hip 
arthroplasties,28 the higher rate of revision surgery for 
RSA recorded on the UK national joint registry29 and 
increased costs associated with RSA,30 it seems increas-
ingly difficult to justify the use of this technology. We 
will, however, continue to review the patients in this 
trial with a further report planned at a minimum of 10 
years.
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